Building a Data-Led Cancer Management Strategy for a Public Education Organization
Jun 11, 2026
A Pennsylvania public education service organization was facing unusually high cancer-related claims within its employee health plan. IMA identified that cancer was not only a growing national cost driver, but an outsized and persistent issue in this population, with more claimants, higher costs, and more severe diagnoses than expected.
The client’s plan was experiencing unsustainable cost pressure, including annual increases in the 10%–12% range driven heavily by cancer claims. The situation was especially complex because diagnoses were appearing in a younger population that may be less likely to receive routine screenings, and no single vendor could address prevention, early detection, treatment navigation, and complex care support in one solution. Maintaining the status quo meant continued cost escalation and poorer member outcomes.
From insight to coordinated, multi-stage solution.
IMA’s employee benefits team acted to support the client by:
This approach worked because IMA did more than flag rising costs. The team translated data into a practical strategy, involved the client throughout an iterative decision-making process, and helped assemble a coordinated solution around both financial stewardship and member experience. The work was supported by analytics, cross-functional collaboration, and a willingness to guide the client through a less traditional but high-potential approach.
This story demonstrates how IMA can use data to uncover hidden plan risks and then help clients build tailored, multi-part solutions rather than relying on a single-point fix. Other teams can apply the same model: let the data guide the opportunity, involve the client early, and draw on internal expertise when evaluating emerging or more complex solutions.
After an initial investment of roughly $200,000 to $250,000, the program produced two early-stage cancer identifications within the first six months, with estimated savings exceeding the initial spend. Just as important, the early findings improved treatment outlooks, increased employee appreciation for employer-funded screening access, and gave the client enough confidence to expand eligibility for the program.